The Economic Modern Family Remains Technically Intact

Mish Schneider | January 8, 2025

I have read so many scary headlines this week. 

And let’s face it, the sell-off, especially in quantum computer stocks, is sobering. 

Please though, pay attention to price and not headlines or you will go nuts. 

If there is ever …


Turnaround Tuesday: Without Our Health…Moderna MRNA

Mish Schneider | January 7, 2025

In the Outlook 2025 I list 10 picks.  

But then, I end with Honorable Mention stocks that I describe as “These stocks faced challenges in 2024, but as we approach 2025, they show promising fundamentals and charts with clear support …


Technical Monday: Corn Futures and ETF Worth Watching

Mish Schneider | January 6, 2025

In the Outlook 2025 CORN, the ETF, is an honorable mention pick for this year.

I use a monthly chart in the report as a longer-term viewpoint. For CORN to regain a 6-7-year business cycle expansion or go through the …


For 2025, Enter a Different Market Analyst’s Classroom

Mish Schneider | January 5, 2025

One lesson I have learned in this business is to never take a victory lap until you are at least 2x profitable from an entry point on any given trade.

However, with that said, it is perfectly ok to feel …


Happy New Year or Is It for The Economic Modern Family?

Mish Schneider | January 2, 2025

I hope everyone had a wonderful holiday and has a very happy and successful New Year. 

I spent time with my actual family and of course, watched my Economic Economic Modern Family carefully. 

If you have not seen my Outlook …


Turnaround Tuesday: Will the Fed be Naughty or Nice?

Mish Schneider | December 17, 2024

While NASDAQ 100 and many of the Mag 7 went on to make new highs, RSP the S&P 500 Equal Weight ETF shows a different picture. 

The Daily chart of QQQs does not exactly suggest a turnaround Tuesday after making …


Technical Monday: Why Watch AbbVie Inc

Mish Schneider | December 16, 2024

AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. 

AbbVie focuses primarily on immunology, oncology, neuroscience, and virology treatments, and it has a broad portfolio of prescription drugs aimed at …


Economic Modern Family-Buy This Dip?

Mish Schneider | December 15, 2024

From my last Daily: 

“But, unless the market continues to broaden, we can almost take the Mag 7 stocks outperforming as a lack of confidence…Unless small caps can deliver.” 

As we ended this week, clearly NASDAQ held up better than …


NASDAQ Rallies-But What About Market Broadening?

Mish Schneider | December 11, 2024

While the NASDAQ 100 made new all-time highs today climbing over 20,000, all the Mag 7 talking heads cheered! 

And as they should. After all, it’s been all about growth stocks for years and every dip has been a buy. …


Turnaround Tuesday: 3-D Printing, Finally

Mish Schneider | December 10, 2024

An Israeli company, Stratasys Ltd., saw shares climb after the company raised its earnings outlook for the year and unexpectedly turned an adjusted profit in the third quarter. 

I have waited for a very long time for companies who pioneer …